Clinical trials provide information on the benefits, side effects and possible uses for new drugs. They are also conducted to study new uses for existing medications. Results from clinical trials are submitted for review to regulatory agencies, like the U.S. Food and Drug Administration (FDA), which establish safety and efficacy standards for medical products. If a medicine meets these standards, it can be approved and becomes available by prescription.
The National Institutes of Health offers up-to-date information on clinical trials for a wide range of diseases and conditions at www.clinicaltrials.gov.
Information on all clinical trials involving products being developed by Acorda is posted here.
You are now leaving the Acorda.com site. By clicking "Ok", you will be leaving this website (sponsored by Acorda Therapeutics, Inc.) to enter an external and entirely independent website.
Acorda.com provides this link as a service and assumes no responsibility for any information presented on external websites.
If you’ve been impacted by Hurricane Harvey, Irma, or Maria, and have concerns about your Ampyra (dalfampridine) prescription, please contact your Specialty Pharmacy or Ampyra Patient Support Services at (888) 881-1918
Acorda has acquired Biotie Therapies. We invite you to explore www.acorda.com to learn more about our company, including our continued development of BIotie clinical programs for tozadenant, SYN120 and BTT1023. Information regarding transfers of value made to healthcare professionals and healthcare organizations in connection with Biotie’s clinical development programs is also available.